Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MWfDfZRwfG:6aXOgRZN{[Xl? NH;UZWsyOCCwTR?= NHjtZ5g4OiCq NYfIdYlCTE2VTx?= NFHVNHRRd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> MorPNlQ6ODB6N{O=
HT-29 Mn\PR5l1d3SxeHnjJGF{e2G7 NHS4XogyOCCwTR?= MmHqO|IhcA>? NV;Kc3FETE2VTx?= NXvuPVhpWG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 MmnENlQ6ODB6N{O=
HT-29 M1O3[2N6fG:2b4jpZ{BCe3OjeR?= NGXD[2UyOCCwTR?= M2fBUVczKGh? NVW0enUyTE2VTx?= NXHTU5k{WG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? Mkj3NlQ6ODB6N{O=
PC3 MUDLbY5ie2ViQYPzZZk> MmOzNVAxKG6P MVuxJIg> M3z6XGROW09? NYHhTZcyWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> MkXqNlE6Pzh4OEO=
PC3 NWjuRpVWU2mwYYPlJGF{e2G7 M3[2dlExOCCwTR?= MmPsNUBp NGPxN4ZFVVOR NYXF[ZcxTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MmGzNlE6Pzh4OEO=
PC3 NGLw[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXpOoIyNjVizszN M{O3d|EhcA>? NGH4TldFVVOR M4DRdGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NFzDZ44zOTl5OE[4Ny=>
HEK293 NXnDRoZWTnWwY4Tpc44hSXO|YYm= NWfFZplyOTByIH7N M2L2TFghcA>? M{T2emROW09? NGDLO|BKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NFTkRmkzOTV|OUOwNS=>
BT-20 M3rENmtqdmG|ZTDBd5NigQ>? MYCyNEDPxE1? MUPEUXNQ MnTvSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? NVSw[4lXOjF|NUO1OVE>
U937 NIfvNohCdnSrYnHjeIVzcWGuIFHzd4F6 MUC1NEDPxE1? MmHFOFghcA>? MVjEUXNQ M1zWW2lv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= NW\oN3g4OjFzNEKxNFY>
U937 NGnKc3NCdnSrYnHjeIVzcWGuIFHzd4F6 NGHPO3Y2OCEQvF2= NI\zc|U1QCCq NUPL[WplTE2VTx?= NEXPSohFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| MlzQNlEyPDJzME[=
U937 MWTBcpRq[mGldHXybYFtKEG|c3H5 MWS1NEDPxE1? MkjKOFghcA>? MULEUXNQ NF3xS5ZFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? NVvIbYJiOjFzNEKxNFY>
MCF-7 NVjLPI1[SXW2b4DoZYd6KEG|c3H5 MWSzNEBvVQ>? NFXZTFA1KGh? NHjyV49FVVOR MXjJcoR2[2W|IHH1eI9xcGGpeR?= MoXQNlAxOjhzM{S=
U87MG MonQT4lv[XOnIFHzd4F6 NEnPV40yKM7:TR?= MkHjOkBp M1;scWROW09? NVe1WZJpWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= MVyxPVg1QDRyNB?=
U87MG M{C5dGtqdmG|ZTDBd5NigQ>? NYDafWpuOSEQvF2= NIDmd|E3KGh? MlXaSG1UVw>? MVfQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NIHmdWgyQTh2OESwOC=>
U87MG NV7xbmFYU2mwYYPlJGF{e2G7 NYXkcJNyOSEQvF2= MV22JIg> MnHUSG1UVw>? M1;UUWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w M{LQd|E6QDR6NEC0
U87MG MXLLbY5ie2ViQYPzZZk> NFjrPIsyKM7:TR?= MnT6OkBp MYPEUXNQ Mn[2SI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v MVqxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb M1y5VmF2fG:yaHHnfUBCe3OjeR?= Mk\pNE4zKM7:TR?= M3fCeVI1KGh? M1TCZmROW09? MYPJcoR2[2W|IHH1eI9xcGGpeR?= NFzyV5IyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 MXnBeZRweGijZ4mgRZN{[Xl? MV[wMlIh|ryP NEfPRWczPCCq MUjEUXNQ NYX4SVlCUW6mdXPld{BifXSxcHjh[5k> NWLNSlY1OTh|OUG5OFk>
H4 NFHx[oxHfW6ldHnvckBCe3OjeR?= NHHuTokxNjJizszN M{XYZ|I1KGh? NYfMeJl3TE2VTx?= M1nzS2lv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> M1\Ec|E5ODJ2NUi0
HeLa NImzfI9HfW6ldHnvckBCe3OjeR?= MYWxNFAhdk1? NX3IUWRNOzZiaB?= NYGyXpllTE2VTx?= NXPwPFR7UW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? M{nFd|E4PTZ|M{i1
HeLa M2GwWWZ2dmO2aX;uJGF{e2G7 NFvveYEyODBibl2= MV[zOkBp NYfGUYZLTE2VTx?= MYHJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NX3JR3lOOTd3NkOzPFU>
HeLa MoTMSpVv[3Srb36gRZN{[Xl? MoHjNVAxKG6P NFTqc2E{PiCq NH3iU5pFVVOR MmTsTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NHe2fmYyPzV4M{O4OS=>
SYF NW\M[Yt4TnWwY4Tpc44hSXO|YYm= M4fk[|ExOCCwTR?= NHXoSJIzPCCq NE\5dGNFVVOR NYjJV2R7UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NY\V[WxOOTd3NkOzPFU>
SYF MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPzcngyODBibl2= M4LYNFI1KGh? Mle1SG1UVw>? NYHETot7UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> M1XCZlE4PTZ|M{i1
HEK293T MkLoRY51cX[rcnHsJGF{e2G7 MkDINUBvVQ>? MoHvOEBl MoLFSG1UVw>? MUfJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= M4\MTlE4PDh3NUCx
HEK293T MknlRY51cX[rcnHsJGF{e2G7 NFrkTXkyKG6P Mn;lOEBl NWfjfW5rTE2VTx?= M1q5VWlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N M13Q[|E4PDh3NUCx
PBMC M2S1SWZ2dmO2aX;uJGF{e2G7 MYSxJI5O MWGxOEBl NGnNZ3lFVVOR NHPJbIZT\WS3Y3XzJGNEWjViZHXud4l1gQ>? M4\kTlE4PDh3NUCx
PBMC M4fjR2Z2dmO2aX;uJGF{e2G7 MVWxJI5O M160UFE1KGR? NHeyW4tFVVOR Mn;ISI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> M4fzTFE4PDh3NUCx
HEK293 cells NXvZfGVVU2mwYYPlJGF{e2G7 MoniOVAhdk1? M3vrWVQ2KG2rbh?= MmfvSG1UVw>? MnvsTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? MnL2NVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MV3GeY5kfGmxbjDBd5NigQ>? NIrNOYQyODBibl2= MUS0JIg> MUTEUXNQ MlLGTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> MVGxO|EzQDJ4Mh?=
Human mixed lymphocyte MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7QWnVOPSCwTR?= NWXqRnUyTE2VTx?= M{W0cmlEPTB;MT62JI5ONg>? MVuxOlE5PTh4NR?=
Lewis rat lymph node cells MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q1XFUh|ryP M4exVWROW09? M4\Ze2lEPTB;Mj62JO69VQ>? NXvHXYdCOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7RbYQyOCCwTR?= NXzUfVZRPzJiaB?= NGr6cHFFVVOR MWTJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P MV6xNFAzOTl2OB?=
MRK-nu-1 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzYR5JKSzVyPUCuPFQ2KHCP M{DoXnNCVkeHUh?=
OCUB-M NUHU[Vc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7KbHFNUUN3ME21MlI1KHCP NXqyUnpIW0GQR1XS
SF539 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFzLk[gdG0> NGDpN4NUSU6JRWK=
ES4 NHXKXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJzLkWgdG0> MYnTRW5ITVJ?
RL95-2 M1PSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPJc45JUUN3ME2xNFcheE1? MmPvV2FPT0WU
LC-2-ad MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XqXWlEPTB;NEKzJJBO MX7TRW5ITVJ?
Daudi NVrhWZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzCZ|FFUUN3ME20N|QheE1? M1\YbXNCVkeHUh?=
NTERA-S-cl-D1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTR2MzDwUS=> MVHTRW5ITVJ?
OS-RC-2 M4S0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK2OnlKSzVyPU[1NkBxVQ>? NXnqNGJXW0GQR1XS
VA-ES-BJ NGO4TllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fV[2lEPTB;N{KzJJBO M3mzXHNCVkeHUh?=
GR-ST M4\jdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTh2NjDwUS=> Mk\hV2FPT0WU
SW872 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSwOGJKSzVyPUi0OkBxVQ>? Mo\vV2FPT0WU
NOS-1 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Ke2lEPTB;OEexJJBO MUfTRW5ITVJ?
MC116 NF7hfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PBbGlEPTB;OUi1JJBO MVHTRW5ITVJ?
NCI-H1355 M4PJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHlTWM2OD1zLkCxJI5O M370dnNCVkeHUh?=
RPMI-8226 NIXnRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknCTWM2OD1zLkG5JI5O NVTLbnplW0GQR1XS
TE-15 NFLkdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTCNoNtUUN3ME2xMlM3KG6P MoX0V2FPT0WU
Ramos-2G6-4C10 M3rPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;VcYJKSzVyPUGuOFYhdk1? M3npOnNCVkeHUh?=
KU812 NWDFc2RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwMEGgcm0> NFrt[I1USU6JRWK=
EW-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwMUegcm0> NFrxWmxUSU6JRWK=
KS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwNEWgcm0> NIrZfJRUSU6JRWK=
SK-LMS-1 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rCOWlEPTB;Mj60PUBvVQ>? NEnJNWlUSU6JRWK=
TGBC1TKB NH3TVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfk[VVmUUN3ME2yMlY6KG6P NEfwXWJUSU6JRWK=
TE-6 M2TUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\hVmlEPTB;Mj63O{BvVQ>? MlTsV2FPT0WU
ETK-1 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJwOEKgcm0> MoK5V2FPT0WU
BE-13 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwOUmgcm0> NXnFUWRrW0GQR1XS
A3-KAW NELxWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;icFEyUUN3ME2yMlk6KG6P MYLTRW5ITVJ?
TE-10 NHjRU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH23N4VKSzVyPUOuN{BvVQ>? MXPTRW5ITVJ?
DOHH-2 NUC2c2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwM{Wgcm0> MXXTRW5ITVJ?
ES6 NHTnPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T5NWlEPTB;Mz60N{BvVQ>? MYnTRW5ITVJ?
OPM-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTiSnZKSzVyPUSuNVUhdk1? MVnTRW5ITVJ?
SH-4 NFjHUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\JNW9KSzVyPUSuN|Qhdk1? M{L1THNCVkeHUh?=
NB13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ZN3pDUUN3ME20MlM3KG6P M3XzZ3NCVkeHUh?=
HUTU-80 NF7ic5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTRwNEKgcm0> Mke4V2FPT0WU
CCRF-CEM MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzkWFZKSzVyPUSuPVQhdk1? M1XhO3NCVkeHUh?=
TGBC24TKB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS5fZJWUUN3ME21MlUyKG6P MYfTRW5ITVJ?
697 NGXSdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTZwMkigcm0> NHvqfYdUSU6JRWK=
J-RT3-T3-5 NXzl[GxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfBRmhKSzVyPU[uOFYhdk1? NVrHdXp[W0GQR1XS
KALS-1 NUjLWpNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTZwNU[gcm0> MVjTRW5ITVJ?
no-10 NFX3bpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3viOGlEPTB;Nz6yPUBvVQ>? NULXN5pyW0GQR1XS
SK-NEP-1 NX;aRnhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRThwN{mgcm0> MkiyV2FPT0WU
L-540 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXHVYtKSzVyPUGwMlQzKG6P M1PxR3NCVkeHUh?=
JiyoyeP-2003 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PvNmlEPTB;MUCuPVQhdk1? NFTC[WNUSU6JRWK=
HH M3TTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[4ZpBQUUN3ME2xNU4{QSCwTR?= NVjUb|RYW0GQR1XS
SR MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTjTWM2OD1zMT60OUBvVQ>? NIXmPIpUSU6JRWK=
QIMR-WIL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFzLki1JI5O NHi3fodUSU6JRWK=
A4-Fuk NYjYPYRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj5TWM2OD1zMz6xNkBvVQ>? MlfOV2FPT0WU
CESS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzPUWZKSzVyPUGzMlE{KG6P MnHzV2FPT0WU
KE-37 NUn6eppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF4LkC3JI5O M1TXUnNCVkeHUh?=
SK-UT-1 NWq0dWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF4LkixJI5O MnLkV2FPT0WU
SIG-M5 M{jIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7wfWVLUUN3ME2xO{4zPSCwTR?= NY\yVoNjW0GQR1XS
HT MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGyfGYyUUN3ME2xO{43KG6P MU\TRW5ITVJ?
DEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK5TWM2OD1zNz65PUBvVQ>? NYHKVXB7W0GQR1XS
SK-PN-DW NX\JNVY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJyLkKzJI5O MXnTRW5ITVJ?
RPMI-8402 NV;KXndmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJzLke3JI5O MlixV2FPT0WU
RPMI-6666 NIHIdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfkcXpKSzVyPUK0MlQzKG6P NWDDUot3W0GQR1XS
NCI-H720 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDK[XJIUUN3ME2yOU41OSCwTR?= NEHnboNUSU6JRWK=
EW-16 NHLYbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP3XZhqUUN3ME2yOk45PyCwTR?= Mlu4V2FPT0WU
BL-70 M{XHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrDTWM2OD1{OD6zPEBvVQ>? MXTTRW5ITVJ?
SF126 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrUTWM2OD1|MD6zPEBvVQ>? M{SwTXNCVkeHUh?=
BC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG5NoxKSzVyPUOxMlI3KG6P Mm\6V2FPT0WU
MHH-PREB-1 NXXhVndlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjoTWM2OD1|Mj60OEBvVQ>? NF36U5RUSU6JRWK=
A101D NUXzdYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKxXYczUUN3ME2zNk43OiCwTR?= NF3DNHBUSU6JRWK=
NMC-G1 NWmyXJNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHWTWM2OD1|Mz62O{BvVQ>? MVfTRW5ITVJ?
LB1047-RCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPCTWM2OD1|ND62PUBvVQ>? MV7TRW5ITVJ?
EM-2 M1;kZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTYdHRKSzVyPUO4MlU{KG6P NUnuTWF6W0GQR1XS
COLO-684 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HMXmlEPTB;M{muPEBvVQ>? NWm4WnExW0GQR1XS
Becker M2G1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXLTWM2OD12MT6wOUBvVQ>? M{SyU3NCVkeHUh?=
BL-41 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm0TWM2OD12Mz62OkBvVQ>? M1robHNCVkeHUh?=
MDA-MB-134-VI NFz4XHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TpXmlEPTB;NESuNFIhdk1? M2L3TXNCVkeHUh?=
L-363 NFvPO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnHUIFXUUN3ME20OE44OyCwTR?= MX\TRW5ITVJ?
ECC4 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHaTWM2OD12ND63PEBvVQ>? MlzFV2FPT0WU
A388 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHBXGlKSzVyPUS0MlgzKG6P MmHXV2FPT0WU
HEL NYLvc|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r5UmlEPTB;NEmuO|khdk1? NFK0XZdUSU6JRWK=
RKO NX;rPXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDGTWM2OD13MD6yPUBvVQ>? MmTjV2FPT0WU
KINGS-1 NGiz[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\rTWM2OD13MT61OUBvVQ>? NFTIfVlUSU6JRWK=
EB-3 M1XuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnXU2NLUUN3ME21Nk43PyCwTR?= NF\zOFJUSU6JRWK=
ARH-77 M2L2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\0NWhKSzVyPUWyMlghdk1? NVTyd|NWW0GQR1XS
GCIY NFrMWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2np[mlEPTB;NUOuOFYhdk1? NYjBTItHW0GQR1XS
NCI-H1304 NWi5emo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTV5LkKyJI5O MVnTRW5ITVJ?
KARPAS-299 M1nzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTiRohKSzVyPU[xMlgzKG6P MmHtV2FPT0WU
IA-LM NIX1SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPnTWM2OD14OD6xN{BvVQ>? Mn7jV2FPT0WU
GI-1 M3zEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIflW5dKSzVyPUewMlM6KG6P Mmj6V2FPT0WU
TE-11 NWXMTpU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjzWpRTUUN3ME23O{4yPyCwTR?= MX;TRW5ITVJ?
LS-411N NETOZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSzPXhKSzVyPUe3MlU4KG6P NUDIdWFpW0GQR1XS
no-11 M37KNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjB[YVCUUN3ME24N{4zPCCwTR?= M2nCZXNCVkeHUh?=
MV-4-11 NEXqZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Lnd2lEPTB;OEOuO|Mhdk1? NIC2fHRUSU6JRWK=
BV-173 M4SxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL5ZodCUUN3ME24N{46PyCwTR?= MYPTRW5ITVJ?
CMK NGrjUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTh2LkG2JI5O NInEUI9USU6JRWK=
LC4-1 NVjDU5k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvye|VKSzVyPUi2MlczKG6P NYH5OFVrW0GQR1XS
COR-L279 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTh5LkK1JI5O NX;STox{W0GQR1XS
NCI-H209 MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL4d3hKSzVyPUi3MlQyKG6P MVvTRW5ITVJ?
Raji MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTtfW43UUN3ME24PU44OiCwTR?= MY\TRW5ITVJ?
LB996-RCC M13wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jR[mlEPTB;OUOuOFMhdk1? MVHTRW5ITVJ?
NCI-H526 NEfZS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG5epd[UUN3ME25N{42QSCwTR?= MlXxV2FPT0WU
KGN MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTl4LkK5JI5O NWLTbGNKW0GQR1XS
MOLT-4 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M332ZmlEPTB;OU[uO|khdk1? MXnTRW5ITVJ?
PF-382 NFzBPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LiU2lEPTB;OU[uO|khdk1? M{\HSnNCVkeHUh?=
BC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXvc4N[UUN3ME25PU4yQCCwTR?= M{\tR3NCVkeHUh?=
KARPAS-422 NXryS|NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfmUppKSzVyPUGwNk4xQSCwTR?= MX;TRW5ITVJ?
SBC-1 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7iTWM2OD1zMEeuO|Uhdk1? NV3mNpdvW0GQR1XS
LC-1F MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHtTWM2OD1zMEiuNFUhdk1? MnnKV2FPT0WU
GB-1 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTFTWM2OD1zMEmuNFIhdk1? Mkj1V2FPT0WU
SNB75 NYDtUmNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfwdJBwUUN3ME2xNVkvPjlibl2= MoPYV2FPT0WU
BB65-RCC NFzhOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojyTWM2OD1zMUmuPVMhdk1? MoS4V2FPT0WU
NCI-N87 NF3I[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvVTWM2OD1zMkGuPVghdk1? MX7TRW5ITVJ?
IST-MEL1 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fyc2lEPTB;MUKyMlM5KG6P NXTQToMzW0GQR1XS
HOP-62 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnLO5dKSzVyPUGyOk45QSCwTR?= MU\TRW5ITVJ?
ACN M4Xp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK1XHJDUUN3ME2xOFYvPzVibl2= NXjHPVh7W0GQR1XS
DMS-114 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiwW4VKSzVyPUG1NE43PyCwTR?= NWXxPVRFW0GQR1XS
MLMA NUnXdoNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvLTWM2OD1zNUmuPFghdk1? M3PrXXNCVkeHUh?=
HT-144 M1Tn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGxN2JHUUN3ME2xOlUvPDNibl2= MYLTRW5ITVJ?
C2BBe1 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPRPZM5UUN3ME2xOlcvPzZibl2= MkKwV2FPT0WU
L-428 NYHF[XVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL2TWM2OD1zN{euO{BvVQ>? MWTTRW5ITVJ?
DU-4475 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF6Nz62PEBvVQ>? NHrIc|hUSU6JRWK=
CP67-MEL NYDTPJBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDSR|RKSzVyPUG5PU4{QCCwTR?= M2jJSXNCVkeHUh?=
MEG-01 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJyMT65OkBvVQ>? M2DXenNCVkeHUh?=
IST-SL2 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vCTGlEPTB;MkC4MlY{KG6P M2HsSHNCVkeHUh?=
ES8 M2e5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XHfmlEPTB;MkK1Mlk1KG6P MVnTRW5ITVJ?
COLO-800 NUDkeW1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIThPGNKSzVyPUKzOU4zQCCwTR?= M17KbHNCVkeHUh?=
MFH-ino MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfYTWM2OD1{M{WuPFQhdk1? M{G0O3NCVkeHUh?=
OVCAR-4 M12xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHKTWM2OD1{M{euNlQhdk1? MYTTRW5ITVJ?
PSN1 M2mxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ2Mj63NUBvVQ>? MkDWV2FPT0WU
EW-12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O2fWlEPTB;MkSzMlEhdk1? MmrDV2FPT0WU
HCC1599 NX71PFRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPPTWM2OD1{NkGuOFchdk1? M4XUd3NCVkeHUh?=
SJSA-1 NF\mVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJ5MT60OkBvVQ>? M1n6b3NCVkeHUh?=
ST486 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ7Nj6xOEBvVQ>? MkjJV2FPT0WU
NOMO-1 NGTXTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjHRnFbUUN3ME2zNFAvOjFibl2= MlvqV2FPT0WU
MN-60 NIrNR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOwTmhKSzVyPUOwOU4{OiCwTR?= NGfLc4VUSU6JRWK=
HCC1187 M{jRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7GWIFKSzVyPUOwO{4zPSCwTR?= NVLXfVlnW0GQR1XS
SW982 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNzND63OUBvVQ>? NWDBcYlPW0GQR1XS
LB647-SCLC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3FTWM2OD1|MkiuO|Ehdk1? Mo\SV2FPT0WU
HC-1 M2Hvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTN|NT61JI5O MXrTRW5ITVJ?
EHEB NHvaTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXycJJKSzVyPUOzO{42OiCwTR?= M4HpN3NCVkeHUh?=
TUR NIrtR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN4Mz65OUBvVQ>? MofaV2FPT0WU
LU-139 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTN5OD6wNkBvVQ>? NVPD[mxQW0GQR1XS
NB1 NVP2OJdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqzTWM2OD1|OESuOFUhdk1? MoTyV2FPT0WU
BB30-HNC NIHCRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XxOGlEPTB;M{i4MlMzKG6P NEjzc5JUSU6JRWK=
HAL-01 NH;2TWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTN6OT6yOkBvVQ>? MnH3V2FPT0WU
K5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33idWlEPTB;NEGxMlM4KG6P MV;TRW5ITVJ?
MZ2-MEL NWnrRm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTRzMz62OEBvVQ>? M{nUZ3NCVkeHUh?=
RXF393 NYrPV2ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqzNnBjUUN3ME20NVYvPDVibl2= NVm1[|JLW0GQR1XS
NCI-H1648 M1zFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrOVVlKSzVyPUSxO{42OyCwTR?= MkHaV2FPT0WU
TE-12 NX;WVY1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP6bY5NUUN3ME20N|QvOjZibl2= M4j4TXNCVkeHUh?=
EoL-1- NIG3cZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnEOnQ{UUN3ME20N|cvQThibl2= MYDTRW5ITVJ?
JAR MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTnZZlOUUN3ME20N|gvPjJibl2= NVy1WmxzW0GQR1XS
DSH1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXlNG1KSzVyPUS1PE46OSCwTR?= NEHNNZRUSU6JRWK=
NCI-H187 NFHoTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnwN2lZUUN3ME20OlIvQDFibl2= NIXZT45USU6JRWK=
HCE-4 NGrhfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTkTGl[UUN3ME20O|cvPjZibl2= MYDTRW5ITVJ?
8-MG-BA M1LPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTV6MT61NkBvVQ>? NYTSdmtUW0GQR1XS
KLE MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnoTWM2OD13OEWuNkBvVQ>? MUXTRW5ITVJ?
KNS-42 NHvVOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLRfVFQUUN3ME21PFYvQDFibl2= NHrnOXZUSU6JRWK=
MSTO-211H M2DSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPX[INxUUN3ME22NFkvPzRibl2= MUDTRW5ITVJ?
GDM-1 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO1TWM2OD14MUSuNFkhdk1? MojEV2FPT0WU
TE-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX1WIpXUUN3ME22OFYvOTJibl2= NGTZTFdUSU6JRWK=
BT-474 NVXYZmpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZ2Nz6wOkBvVQ>? NInjem9USU6JRWK=
KARPAS-45 NFvKZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjxT29RUUN3ME22OFcvPiCwTR?= NF3OTGdUSU6JRWK=
MOLT-16 NUTFZYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\C[3lNUUN3ME22OFcvQTNibl2= M3PkbnNCVkeHUh?=
KURAMOCHI MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTZ3Nz61NUBvVQ>? MVzTRW5ITVJ?
K-562 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXMTWM2OD14NkmuOVEhdk1? NY[0Ro9kW0GQR1XS
EKVX NWL3eWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLKT4NPUUN3ME22O|IvPzFibl2= M4L4bnNCVkeHUh?=
GAK NEPVcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj2cHNqUUN3ME22O|UvOyCwTR?= MW\TRW5ITVJ?
NCI-SNU-5 NELZVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD0NmxZUUN3ME22PVAvODFibl2= MnL5V2FPT0WU
NCI-H2126 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTd{Nj64O{BvVQ>? NYjnSlZjW0GQR1XS
CTV-1 NWqwToRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P6[GlEPTB;N{S0Mlkhdk1? MWHTRW5ITVJ?
SW962 NXzjSHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTd2OD60OEBvVQ>? MXTTRW5ITVJ?
MONO-MAC-6 NWG4elZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:wNmpKSzVyPUe1Ok46OyCwTR?= NWTUVJV4W0GQR1XS
NCI-H748 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTd3OD65PUBvVQ>? MmCzV2FPT0WU
NCI-H524 NIW1PVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTd6MD63N{BvVQ>? MX7TRW5ITVJ?
LS-123 NWDsW|B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTd7NT62PUBvVQ>? M2fGOnNCVkeHUh?=
NB7 NHi3NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSzbGZoUUN3ME24NVQvOTRibl2= NGq3[WNUSU6JRWK=
LS-1034 NWn1bGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvIdYVKSzVyPUiyPE46QCCwTR?= NGLBPY9USU6JRWK=
TE-5 M13w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;QWm1mUUN3ME24PFMvPTZibl2= MnLwV2FPT0WU
A704 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfjXGRKSzVyPUi5PU4yPSCwTR?= MWHTRW5ITVJ?
TK10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvHTWM2OD17MU[uNFMhdk1? NVrveHBmW0GQR1XS
NCI-H345 NFjaNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DyUmlEPTB;OUSzMlIzKG6P MknWV2FPT0WU
CGTH-W-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTl2OD6xN{BvVQ>? NWrKd2cyW0GQR1XS
NCI-H510A M{fFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\M[YVKUUN3ME25PFUvOTJibl2= M3LtenNCVkeHUh?=
NCI-H1963 M3;ETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrxW|JKSzVyPUGuNFMzQTJizszN MojUV2FPT0WU
SCC-3 NUGzUnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnubYxKSzVyPUGuNFM1OTRizszN NFm5VmtUSU6JRWK=
EW-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF21cJpKSzVyPUGuNFg4PDNizszN M3fCcXNCVkeHUh?=
CPC-N MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrhTWM2OD1zLkC4PEDPxE1? MoCxV2FPT0WU
NCI-H1417 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjZcJpsUUN3ME2xMlEzOjZizszN M2XHVnNCVkeHUh?=
DG-75 M{LBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDuT3VKSzVyPUGuNVYzQDVizszN NX\yRWxNW0GQR1XS
HD-MY-Z MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;3S2lEPTB;MT6xOlQyPiEQvF2= MmLuV2FPT0WU
ATN-1 NV\iU4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vCRmlEPTB;MT6yOlIxQSEQvF2= M4S2SHNCVkeHUh?=
KM-H2 M2nVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O4UWlEPTB;MT6yOlQxQCEQvF2= MWDTRW5ITVJ?
NCI-H2081 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXnTWM2OD1zLkK2OlM4KM7:TR?= M1nCVXNCVkeHUh?=
HL-60 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjzdWdSUUN3ME2xMlI3QTV7IN88US=> M17o[nNCVkeHUh?=
DB MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vPVmlEPTB;MT6yO|I1OiEQvF2= MX7TRW5ITVJ?
NCI-H1522 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTweHRKSzVyPUGuNlg5QDdizszN NIXhd3VUSU6JRWK=
AM-38 NULHUlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwM{C3NkDPxE1? MmjrV2FPT0WU
NCI-H446 NHfwXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\ZR3M3UUN3ME2xMlMzOTJzIN88US=> MUTTRW5ITVJ?
SU-DHL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwM{K4NFEh|ryP NXLYc4pWW0GQR1XS
NH-12 NX7VTZRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwM{[zO|Qh|ryP MVjTRW5ITVJ?
DMS-79 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjCbIhKSzVyPUGuN|Y5PjZizszN MlHsV2FPT0WU
NCI-H716 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\sTWM2OD1zLkO4PVg3KM7:TR?= NX7QU3JqW0GQR1XS
ML-2 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XIU2lEPTB;MT60NVUzQSEQvF2= M{SwWnNCVkeHUh?=
NB10 NWra[2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\3fXRXUUN3ME2xMlQ3PjN{IN88US=> MkfRV2FPT0WU
ONS-76 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXZTWM2OD1zLkWzOVY6KM7:TR?= MnzwV2FPT0WU
LOUCY NGCzd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HEZmlEPTB;MT61OFY2PyEQvF2= NEXONJhUSU6JRWK=
SCLC-21H M3rUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3xTWM2OD1zLkW4OVgzKM7:TR?= MXPTRW5ITVJ?
TGW M1zmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jzcmlEPTB;MT62N|k4PSEQvF2= NGW5eYdUSU6JRWK=
LXF-289 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\LUI9KSzVyPUGuO|MzPjhizszN NFXpOJRUSU6JRWK=
BB49-HNC NF7BSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP1TWM2OD1zLkezOVg3KM7:TR?= NXLYTYFLW0GQR1XS
NCI-H747 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwN{WzOFYh|ryP MVjTRW5ITVJ?
LU-165 NVzMcY9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXLTWM2OD1zLki0PVg3KM7:TR?= NFHiVW1USU6JRWK=
OMC-1 NF7BSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW3Z5R5UUN3ME2xMlk2ODZ4IN88US=> NGGycINUSU6JRWK=
RCC10RGB NH7SZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFPHNKSzVyPUGuPVU5OTdizszN MnjmV2FPT0WU
SW684 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDHTWM2OD1zLkm2NFk6KM7:TR?= NXKyboNqW0GQR1XS
TE-8 NFLxcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwMEW1OVkh|ryP MWrTRW5ITVJ?
SK-N-DZ M4[4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7WPIFKSzVyPUKuNVMzPzRizszN M4XG[3NCVkeHUh?=
EVSA-T MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrwPHpRUUN3ME2yMlE4OzF3IN88US=> NGrBVVRUSU6JRWK=
KASUMI-1 NULvXIpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TESGlEPTB;Mj6xPFgyPSEQvF2= MmTaV2FPT0WU
NKM-1 NVv5TFU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXsTWM2OD1{LkK1OFczKM7:TR?= M{\pOXNCVkeHUh?=
CAL-148 M2DLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHxTWM2OD1{LkOzOlE1KM7:TR?= M33HWHNCVkeHUh?=
NCI-H64 NGTJWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXGNJFZUUN3ME2yMlM1OjN{IN88US=> Mme4V2FPT0WU
KNS-81-FD NXLQ[29GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXOTWM2OD1{LkO2OlIh|ryP Moj3V2FPT0WU
KM12 M2e3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwNEC4N|kh|ryP Ml\zV2FPT0WU
SW954 NXTIVYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwNEe3O|kh|ryP M1fNdXNCVkeHUh?=
NCI-H1395 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxTWM2OD1{LkWyOlQ2KM7:TR?= NGrJS|VUSU6JRWK=
DJM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnDTWM2OD1{Lk[wOlMh|ryP NHXwUYdUSU6JRWK=
COLO-668 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rudWlEPTB;Mj64NlY6PSEQvF2= NVHhWIp2W0GQR1XS
NCI-H1436 M4jyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\xfYpKSzVyPUKuPFU3OTVizszN Moj5V2FPT0WU
LB2241-RCC NIHvXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzWVItnUUN3ME2yMlg3QDN7IN88US=> M3jqfHNCVkeHUh?=
GT3TKB M2fFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwTWM2OD1{Lki5NFU2KM7:TR?= MmrGV2FPT0WU
COLO-824 M1H4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPyXXdKSzVyPUKuPFk4PjhizszN MXnTRW5ITVJ?
ES1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy4XGhqUUN3ME2yMlg6QDd7IN88US=> MlS0V2FPT0WU
LB771-HNC Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\OTWM2OD1{LkmwPVQ3KM7:TR?= MoG2V2FPT0WU
GI-ME-N M4iz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNwMEC5NFQh|ryP NEm4eZJUSU6JRWK=
NALM-6 NV7EZmFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7STWM2OD1|LkCwPVM{KM7:TR?= NWCyZ2xPW0GQR1XS
LU-134-A NGDCVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq2W2RFUUN3ME2zMlA2PDJ3IN88US=> MWTTRW5ITVJ?
DMS-153 NGPUdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNwMEW4NlQh|ryP NEHUXWxUSU6JRWK=
MZ1-PC NELsfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;qTWM2OD1|LkC5NFc5KM7:TR?= NWXaO2d1W0GQR1XS
NCI-H1155 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfDUHlJUUN3ME2zMlEyPjFizszN MYrTRW5ITVJ?
CAS-1 M4nlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33VOGlEPTB;Mz6xN|cxPyEQvF2= NGWy[oRUSU6JRWK=
D-502MG MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LMNWlEPTB;Mz6xOFM6KM7:TR?= M17He3NCVkeHUh?=
NCI-H2141 NXe4WYZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HCcWlEPTB;Mz6xO|Q2OiEQvF2= M{[5U3NCVkeHUh?=
NB6 NUTUdFE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULDXodRUUN3ME2zMlE5OjV7IN88US=> MWnTRW5ITVJ?
NCCIT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf4TWM2OD1|LkKxPFA6KM7:TR?= M{CyUHNCVkeHUh?=
NB69 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFWWlEPTB;Mz6zNVg6OSEQvF2= NH\3[W1USU6JRWK=
JVM-2 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y5e2lEPTB;Mz6zOlQ{OyEQvF2= Ml\UV2FPT0WU
K052 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwM{e5Olgh|ryP MV;TRW5ITVJ?
HCC2157 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm0TWM2OD1|LkWzNlI5KM7:TR?= NXnwWG1wW0GQR1XS
KMOE-2 NFLuSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7QTWM2OD1|LkW0NlQzKM7:TR?= MknpV2FPT0WU
SF268 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LIS2lEPTB;Mz63NVU2PCEQvF2= NV3XfYEyW0GQR1XS
CHP-126 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[1cZE3UUN3ME2zMlc3PDV6IN88US=> NIiydJpUSU6JRWK=
CP66-MEL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m0OmlEPTB;Mz63PVA6PCEQvF2= MVnTRW5ITVJ?
NCI-H69 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH4eZg3UUN3ME20MlAyQTN4IN88US=> NHrEcI1USU6JRWK=
A253 NVPQUop1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwMEKxNFEh|ryP NXftPG1wW0GQR1XS
NB14 NU\l[Xd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjaUI5KSzVyPUSuNVA1PzlizszN NVn6UGhQW0GQR1XS
NCI-H1694 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHWTWM2OD12LkGzNVEzKM7:TR?= NIfUfmNUSU6JRWK=
NCI-H2196 Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTiTWM2OD12LkG3NVY6KM7:TR?= MVvTRW5ITVJ?
TE-9 NGLaTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW5RWhKSzVyPUSuNVc2QDJizszN M3W2eHNCVkeHUh?=
D-283MED M1Xjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfSTWM2OD12LkG4PFQh|ryP M{\wUHNCVkeHUh?=
OCI-AML2 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DUVmlEPTB;ND6xPVQ5QSEQvF2= M1PBZ3NCVkeHUh?=
D-263MG NEflO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD4TWM2OD12LkKyPVYyKM7:TR?= M3r2O3NCVkeHUh?=
MPP-89 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pr[WlEPTB;ND6yO|MxPCEQvF2= NH;tU4VUSU6JRWK=
LAMA-84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TvXGlEPTB;ND6zNFQzOSEQvF2= NInnTYFUSU6JRWK=
LB373-MEL-D NFLYfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H4dWlEPTB;ND6zOlc5QSEQvF2= MknaV2FPT0WU
UACC-257 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXYNmtKSzVyPUSuN|k2OzRizszN NUDjVHJwW0GQR1XS
MC-CAR NUfrUFVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLNTWM2OD12LkSzPVkh|ryP M1HxRnNCVkeHUh?=
COLO-320-HSR M{XrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu1OVZOUUN3ME20MlQ1PDJ5IN88US=> MXrTRW5ITVJ?
P30-OHK NIPkT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12xWWlEPTB;ND62OlU5OSEQvF2= NWLRRml7W0GQR1XS
UACC-812 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17h[mlEPTB;ND62PVE3OSEQvF2= NHHhOm1USU6JRWK=
CTB-1 NIHvNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JU4o5UUN3ME20MlcyPTV3IN88US=> M{nFPXNCVkeHUh?=
ALL-PO M3zYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRwOESwO|ch|ryP NETEeoxUSU6JRWK=
SK-MEL-2 NG\aeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXL[FdKSzVyPUSuPFY6PTVizszN MV;TRW5ITVJ?
TC-YIK NXzPRnZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwOUe5OFIh|ryP M3XVOnNCVkeHUh?=
NCI-H1882 NYroSZd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXL[Jl[UUN3ME21MlAzODBzIN88US=> NYnxVJhlW0GQR1XS
MHH-CALL-2 NVrXdIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TQc2lEPTB;NT6wOVA1OiEQvF2= NXq4Smw2W0GQR1XS
U-87-MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvJW2JKSzVyPUWuNFk1PjZizszN MlvLV2FPT0WU
NCI-H1092 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL1bZZLUUN3ME21MlI3PTV3IN88US=> MnLPV2FPT0WU
TE-441-T NInTe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\wfWlEPTB;NT6yO|gzKM7:TR?= MnixV2FPT0WU
SK-MEL-1 NGTiSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLKTWM2OD13LkK5NFQ1KM7:TR?= MXjTRW5ITVJ?
EW-22 M2j1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnoRpFSUUN3ME21MlI6PDZ4IN88US=> NUfkT5RYW0GQR1XS
MZ7-mel MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTVwNEC2PVEh|ryP NUnaeZBDW0GQR1XS
LP-1 NXvBe4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nEXWlEPTB;NT60NVI6OSEQvF2= MknqV2FPT0WU
NCI-SNU-16 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwNkSwO|Qh|ryP NXLQXlBjW0GQR1XS
LU-65 NF;0SZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwN{[zO|Mh|ryP MmPUV2FPT0WU
CW-2 NX;yVIs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnUZndKSzVyPUWuPFU6PTlizszN NYSycIdPW0GQR1XS
WSU-NHL NFXqW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHTSJFoUUN3ME21Mlk2OTd2IN88US=> MY\TRW5ITVJ?
IST-MES1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[yWmlEPTB;NT65OVQ1OyEQvF2= M2fZTXNCVkeHUh?=
U-266 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITTVFNKSzVyPUWuPVgzODJizszN MnP4V2FPT0WU
TALL-1 M4Ludmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZwMUS2PFgh|ryP NH;KVGFUSU6JRWK=
Calu-6 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DCWmlEPTB;Nj6xOVMyPiEQvF2= NXr2eGZmW0GQR1XS
MMAC-SF NH3NUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDYWm5KSzVyPU[uNVg2PTZizszN NUPqWYd6W0GQR1XS
NCI-H82 M125bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzMRZdKSzVyPU[uNlA1QDlizszN M4jVeXNCVkeHUh?=
RS4-11 NWrnUVdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XjdmlEPTB;Nj6yOVg6PyEQvF2= NEW3R4pUSU6JRWK=
SNU-C2B MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7veGlKSzVyPU[uOFA6PjlizszN NVm3PGViW0GQR1XS
BOKU M{nzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZwNEe1PVch|ryP M4P2VHNCVkeHUh?=
C8166 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwNUW5NVIh|ryP M2XaZXNCVkeHUh?=
D-247MG MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YO5ViUUN3ME23MlA1OzR5IN88US=> MVnTRW5ITVJ?
EW-18 NH3LSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTdwMEeyPVIh|ryP MV;TRW5ITVJ?
KG-1 NGDKcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7hN4lKSzVyPUeuOlI4OzhizszN NWW2ZpY3W0GQR1XS
REH NWjBcZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rYNGlEPTB;Nz62PFExQSEQvF2= M{PxcXNCVkeHUh?=
U-698-M Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnJdlRLUUN3ME23Mlg1OzF3IN88US=> NHvsbJlUSU6JRWK=
KP-N-RT-BM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTdwOUOwNlkh|ryP M{njRnNCVkeHUh?=
MS-1 NVP5cHZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTdwOU[wOFEh|ryP MX;TRW5ITVJ?
SNU-C1 NFXPflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:4eWkyUUN3ME23Mlk5OTl{IN88US=> NWjEcVlnW0GQR1XS
SK-MM-2 NWTNOY41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nIUGlEPTB;OD6yOlA3PSEQvF2= M{jXXXNCVkeHUh?=
LAN-6 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHOSZNKSzVyPUiuN|AxODFizszN NG\icW1USU6JRWK=
NEC8 M3XQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuwTWM2OD16LkOwOlkyKM7:TR?= NV3OTJVCW0GQR1XS
NCI-H1770 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XPNWlEPTB;OD6zPFAxOiEQvF2= MmjDV2FPT0WU
D-336MG Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nwXGlEPTB;OD60NFEyPiEQvF2= MnXkV2FPT0WU
COLO-829 NXnzSnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPUPIlSUUN3ME24MlQ5QDd7IN88US=> MWrTRW5ITVJ?
LS-513 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T5TWlEPTB;OD61PVU6QSEQvF2= NFHNWGJUSU6JRWK=
YT NIPqdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nabGlEPTB;OD62NlQzPyEQvF2= Mon1V2FPT0WU
EW-24 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX2OHp5UUN3ME24Mlc3PTRizszN MnLIV2FPT0WU
IST-SL1 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3myT2lEPTB;OD64OlU1OyEQvF2= NWjYTGJuW0GQR1XS
CA46 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv1TWM2OD16Lkm1NFk5KM7:TR?= M1Lo[HNCVkeHUh?=
NCI-H1838 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLDbGJvUUN3ME24Mlk5PjB{IN88US=> MmPyV2FPT0WU
NCI-H719 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPNTWM2OD17LkK1Nlc6KM7:TR?= NEnVV2tUSU6JRWK=
HCE-T Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPFRlFKSzVyPUmuN|A5PTFizszN MWfTRW5ITVJ?
A498 M{\Gfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr3[G1KSzVyPUmuN|YyOjRizszN MV\TRW5ITVJ?
LB831-BLC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrCXHhKSzVyPUmuO|Y2OjFizszN NH3RcHVUSU6JRWK=
SKM-1 NFrrWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTlwOEW5OlMh|ryP MnmxV2FPT0WU
THP-1 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX0TWM2OD17Lkm2PVE5KM7:TR?= NEnSclJUSU6JRWK=
SHP-77 NX;4NmVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXxTGlUUUN3ME2xNE41ODdizszN M1;tcXNCVkeHUh?=
EW-3 NITnZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n2cmlEPTB;MUCuOlI5QSEQvF2= MmrBV2FPT0WU
KY821 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLkZ|ZZUUN3ME2xNE44PjNizszN NVHqb3dqW0GQR1XS
NCI-SNU-1 M1L4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HiSWlEPTB;MUGuNFIyPyEQvF2= MkPDV2FPT0WU
HCC2218 M1TVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoezTWM2OD1zMT6zPVg3KM7:TR?= MVfTRW5ITVJ?
IM-9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnPTWM2OD1zMT61NVA3KM7:TR?= NUCzTop4W0GQR1XS
NCI-H889 M3X3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi4dI5KSzVyPUGxMlU{OTNizszN MkX3V2FPT0WU
HDLM-2 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vzVGlEPTB;MUKuOFE2QSEQvF2= NFHNc5ZUSU6JRWK=
LB2518-MEL NETz[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ewcGlEPTB;MUKuOlgyPSEQvF2= M3fTeHNCVkeHUh?=
NCI-H23 NFXGTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\TdXRKSzVyPUGzMlI1OjVizszN NUXnfVhoW0GQR1XS
NB17 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fjeGlEPTB;MUOuOFU4QSEQvF2= NUC1UmlbW0GQR1XS
NCI-H322M MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHnUGdKSzVyPUG0MlQxPjhizszN MkXFV2FPT0WU
SUP-T1 NUXUZZR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF2LkSxN{DPxE1? MVXTRW5ITVJ?
ES3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF3LkC3NFMh|ryP NVzCNHdlW0GQR1XS
ES5 M17KXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjOfXFKSzVyPUG1MlA4QDdizszN MVjTRW5ITVJ?
NCI-H1650 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn62TWM2OD1zNT60PVc6KM7:TR?= MVPTRW5ITVJ?
NCI-H226 M3LZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPCZZhkUUN3ME2xOU45PzZ6IN88US=> NFjIeoRUSU6JRWK=
COR-L88 NWO1fXh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\2U2lEPTB;MU[uN|E1KM7:TR?= M{\JNHNCVkeHUh?=
SCC-15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrESVZJUUN3ME2xOk4{QDZ7IN88US=> NUfyWoFjW0GQR1XS
GOTO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfPNpFoUUN3ME2xOk41Pzl|IN88US=> M2fjXXNCVkeHUh?=
SIMA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF4LkS4NFIh|ryP MnTMV2FPT0WU
NCI-H1299 NVPxU2tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF5LkG1PVEh|ryP MlHOV2FPT0WU
NCI-H1581 NELHbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF5LkSyNVkh|ryP NGi1foNUSU6JRWK=
MHH-NB-11 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfvTWM2OD1zNz65Olg{KM7:TR?= MYXTRW5ITVJ?
MFM-223 M1jNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF6LkC1N|gh|ryP MlO5V2FPT0WU
ES7 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TpZmlEPTB;MUiuOVQ{OSEQvF2= M4PT[nNCVkeHUh?=
JVM-3 NVTMTGoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTTWlM4UUN3ME2xPE44OTdizszN M{\pPXNCVkeHUh?=
RL M1GwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S0bmlEPTB;MkCuN|g5KM7:TR?= M2\qc3NCVkeHUh?=
EC-GI-10 MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXoWJBEUUN3ME2yNU4zODRzIN88US=> NF\h[XhUSU6JRWK=
LNCaP-Clone-FGC M2\DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmSyTWM2OD1{MT62O|Y5KM7:TR?= NUi0WWJxW0GQR1XS
IMR-5 NV;uWpNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr5PFNTUUN3ME2yNU45PDl2IN88US=> NEjhfVJUSU6JRWK=
KP-N-YS NGexPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJzLki3OUDPxE1? NFy5UGRUSU6JRWK=
Mo-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W4SmlEPTB;MkKuNlE5PSEQvF2= Ml;wV2FPT0WU
NCI-H128 M2TpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfPe3l6UUN3ME2yN{42QDV|IN88US=> M2fIc3NCVkeHUh?=
RH-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ|Lke4OlYh|ryP MXvTRW5ITVJ?
NCI-H2171 NIHzV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3lOnVKSzVyPUK0MlI1QDVizszN M1LYTHNCVkeHUh?=
RPMI-8866 M4W4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzTTWM2OD1{Nj63OFIh|ryP MXHTRW5ITVJ?
SK-N-FI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnlNWRSUUN3ME2yO{4{QDFzIN88US=> NYnNS|BPW0GQR1XS
LOXIMVI MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r3cWlEPTB;MkeuPFA2OSEQvF2= M4ryOXNCVkeHUh?=
P31-FUJ M1TOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\mTWM2OD1|MT61N|c1KM7:TR?= Mnr4V2FPT0WU
KMS-12-PE M3fKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnl[VJKSzVyPUS5MlU{ODJizszN MmjuV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID